よむ、つかう、まなぶ。
06【参考資料１】Interim statement on the composition of current COVID19 vaccines World Health Organization 17 June 2022 (2 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_26922.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会（第33回 7／22）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
1
performance of COVID-19 vaccines in order to issue timely recommendations on
2
potential modifications to vaccine strain composition. Since the designation of the
3
Omicron VOC by the World Health Organization (WHO) in November 2021, the
4
TAG-CO-VAC has closely followed the impact of Omicron on the performance
5
of currently licensed COVID-19 vaccines to consider whether a change in
6
COVID-19 vaccine composition may be warranted---. Further to the interim
7
statement published on 8 March 2022, this TAG-CO-VAC statement is intended
8
to offer Member States, vaccine developers and regulatory authorities
9
considerations as to whether a modified vaccine composition may be warranted
10
and, if so, how this may be achieved to fulfil the public health objectives of
11
COVID-19 vaccination.
12
13
Is a modified COVID-19 vaccine composition warranted?
14
Since the classification of Omicron as a VOC, there has been rapid and relatively
15
synchronous displacement of other circulating variants by Omicron that has
16
caused substantial epidemic waves in all 6 WHO regions. Omicron is
17
characterized by a large number of mutations, including many in antigenically
18
important regions of the spike (S) protein. Its transmission advantage over other
19
variants has largely been driven by immune escape properties, and Omicron has
20
infected many who had been previously vaccinated and/or infected. Several
21
sublineages within Omicron, notably BA.1, BA.2, BA.3, BA.4 and BA.5, have been
22
identified, which share many of the same S protein mutations.
23
24
In this context, the primary goals of COVID-19 vaccination using currently
25
licensed vaccines continue to be to reduce hospitalization, severe disease and
26
death, and to protect health systems. A primary series of currently licensed
27
vaccines based on the virus that was identified from the first cases of COVID-19
28
in
29
19/Wuhan/WIV04/2019) confers lower levels of protection against severe disease
30
outcomes for Omicron, compared to prior VOCs. However, a booster dose of the
31
currently licensed COVID-19 vaccines based on the index virus appears to restore
32
protection against severe disease and death against currently circulating variants
December
2019
(termed
the
index
2
virus
e.g.
GISAID:
hCoV-
performance of COVID-19 vaccines in order to issue timely recommendations on
2
potential modifications to vaccine strain composition. Since the designation of the
3
Omicron VOC by the World Health Organization (WHO) in November 2021, the
4
TAG-CO-VAC has closely followed the impact of Omicron on the performance
5
of currently licensed COVID-19 vaccines to consider whether a change in
6
COVID-19 vaccine composition may be warranted---. Further to the interim
7
statement published on 8 March 2022, this TAG-CO-VAC statement is intended
8
to offer Member States, vaccine developers and regulatory authorities
9
considerations as to whether a modified vaccine composition may be warranted
10
and, if so, how this may be achieved to fulfil the public health objectives of
11
COVID-19 vaccination.
12
13
Is a modified COVID-19 vaccine composition warranted?
14
Since the classification of Omicron as a VOC, there has been rapid and relatively
15
synchronous displacement of other circulating variants by Omicron that has
16
caused substantial epidemic waves in all 6 WHO regions. Omicron is
17
characterized by a large number of mutations, including many in antigenically
18
important regions of the spike (S) protein. Its transmission advantage over other
19
variants has largely been driven by immune escape properties, and Omicron has
20
infected many who had been previously vaccinated and/or infected. Several
21
sublineages within Omicron, notably BA.1, BA.2, BA.3, BA.4 and BA.5, have been
22
identified, which share many of the same S protein mutations.
23
24
In this context, the primary goals of COVID-19 vaccination using currently
25
licensed vaccines continue to be to reduce hospitalization, severe disease and
26
death, and to protect health systems. A primary series of currently licensed
27
vaccines based on the virus that was identified from the first cases of COVID-19
28
in
29
19/Wuhan/WIV04/2019) confers lower levels of protection against severe disease
30
outcomes for Omicron, compared to prior VOCs. However, a booster dose of the
31
currently licensed COVID-19 vaccines based on the index virus appears to restore
32
protection against severe disease and death against currently circulating variants
December
2019
(termed
the
index
2
virus
e.g.
GISAID:
hCoV-